Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Solasia Pharma K.K. (9SO.F)

Compare
0.1780
+0.0060
+(3.49%)
As of 8:12:52 AM GMT+2. Market Open.
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
316,000
316,000
617,000
1,092,000
559,000
Cost of Revenue
131,000
131,000
280,000
430,000
185,000
Gross Profit
185,000
185,000
337,000
662,000
373,000
Operating Expense
2,135,000
2,135,000
1,476,000
3,133,000
2,793,000
Operating Income
-1,950,000
-1,950,000
-1,139,000
-2,471,000
-2,420,000
Net Non Operating Interest Income Expense
-5,000
-5,000
10,000
-18,000
-23,000
Pretax Income
-1,961,000
-1,961,000
-1,135,000
-2,492,000
-2,442,000
Tax Provision
-19,000
-19,000
-22,000
56,000
35,000
Net Income Common Stockholders
-1,941,000
-1,941,000
-1,112,000
-2,548,000
-2,478,000
Diluted NI Available to Com Stockholders
-1,941,000
-1,941,000
-1,112,000
-2,548,000
-2,478,000
Basic EPS
-9.77
--
-6.62
-16.77
-19.04
Diluted EPS
-9.77
--
-6.62
-16.77
-19.04
Basic Average Shares
198,704.2390
--
168,131.9010
151,986.9080
130,149.2650
Diluted Average Shares
198,704.2390
--
168,131.9010
151,986.9080
130,149.2650
Total Operating Income as Reported
-1,951,000
-1,951,000
-1,139,000
-2,470,000
-2,419,000
Total Expenses
2,266,000
2,266,000
1,756,000
3,563,000
2,978,000
Net Income from Continuing & Discontinued Operation
-1,941,000
-1,941,000
-1,112,000
-2,548,000
-2,478,000
Normalized Income
-1,941,000
-1,941,000
-1,112,000
-2,548,000
-2,478,000
Interest Income
--
--
10,000
--
--
Interest Expense
5,000
5,000
--
18,000
23,000
Net Interest Income
-5,000
-5,000
10,000
-18,000
-23,000
EBIT
-1,956,000
-1,956,000
-1,135,000
-2,474,000
-2,419,000
EBITDA
-1,761,000
-1,761,000
-635,000
-1,940,000
-1,924,000
Reconciled Cost of Revenue
131,000
131,000
280,000
430,000
185,000
Reconciled Depreciation
195,000
195,000
500,000
534,000
495,000
Net Income from Continuing Operation Net Minority Interest
-1,941,000
-1,941,000
-1,112,000
-2,548,000
-2,478,000
Normalized EBITDA
-1,761,000
-1,761,000
-635,000
-1,940,000
-1,924,000
Tax Rate for Calcs
0
0
0
0.0002
0.0003
12/31/2021 - 4/6/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6QC.F Towa Pharmaceutical Co., Ltd.
14.40
-2.70%
 
1MRK.MI Merck KGaA
114.00
+0.84%
 
3D7.F Willow Biosciences Inc.
0.0005
0.00%
 
CAIHF Chia Tai Enterprises International Limited
0.0100
0.00%
 
2WU.F Lowell Farms Inc. R
0.0120
+33.33%
 
0T01.F TILT Holdings Inc.
0.0060
0.00%
 
8Z1.F PharmaEssentia Corporation
0.0000
-100.00%
 
4KF0.F Glass House Brands Inc.
4.2400
0.00%
 
AVCNF Avicanna Inc.
0.1580
-1.86%
 
BSPK Bespoke Extracts, Inc.
0.0788
0.00%